首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到19条相似文献,搜索用时 93 毫秒
1.
表皮生长因子受体在前列腺增生中的作用   总被引:2,自引:0,他引:2  
  相似文献   

2.
目的探讨p53基因产物和雌激素受体(ER)在乳腺不典型增生和乳腺癌中表达及意义。方法用ABC免疫组化法检测乳腺不典型增生和乳腺癌细胞p53基因产物和ER表达。结果乳腺上皮不典型增生Ⅰ级者上皮细胞ER染色结果与正常乳腺上皮细胞相似,不典型增生Ⅱ级ER表达明显增强,22/24例阳性,不典型增生Ⅲ级20/22例见ER染色阳性。在乳腺上皮不典型增生Ⅰ级无p53蛋白表达,不典型增生Ⅱ级、Ⅲ级中分别有3/24和7/22例p53蛋白表达。乳腺癌59例,ER阳性率为36/59(61.02%)。乳腺癌p53蛋白表达阳性22/59(37.29%)。结论p53可促进正常细胞以不典型增生向癌的转化,ER对不典型增生癌变起重要的刺激、激活作用。p53-/ER 代表正常组织、良性增生与高分化和好的预后,p53 /ER-多为不典型增生、低分化癌和差的预后。所以同时检测p53、ER对判断不典型增生向癌的转化及乳腺癌患者的预后有重要意义。  相似文献   

3.
观测正常乳腺、乳腺囊性增生病和乳腺癌细胞核DNA含量、细胞超微结构、Y抗原及免疫抑制性酸性蛋白(IAP2)表达。结果:上皮增生Ⅰ级细胞与正常乳腺细胞相似;不典型增生细胞DNA含量增加,细胞膜和细胞核超微结构出现发育不良及去分化现象,部分不典型增生细胞见异常抗原表达;部分Ⅲ级不典型增生细胞DNA含量和超微结构与乳腺癌组织分化Ⅰ级细胞相似。提示在不典型增生阶段,这些细胞的生物学异常和程度与其细胞分化程度、发展趋势和癌变危险性大小密切相关  相似文献   

4.
甲状腺癌中表皮生长因子受体的表达   总被引:3,自引:0,他引:3  
为了解甲状腺中表皮生长因子受体的表达意义,应用免疫组化方法检测了81例甲状腺癌中EGFR的表达,并与甲状腺腺瘤和癌旁正常甲状腺组织相比较。结果:甲状腺癌中45例EGFR表达阳性,而甲状腺腺瘤及癌旁正常甲状腺组织中均未见EGFR表达。EGFR表达阳性率在甲状腺癌的病理类型,临床分期,浸润程度及淋巴结转移诸因素间接羞匀无统计学意义。  相似文献   

5.
胃癌表皮生长因子及雌激素受体同步表达的临床意义何双梧,郭连营,谢尚奎用免疫组化ABC法检测104例胃癌组织中表皮生长因子受体(EpidermalgrowthfactorreceptorEGFR)和雌激素受体(Estrogenreceptor,ER)表...  相似文献   

6.
乳腺不典型增生癌变过程中基底膜的变化   总被引:2,自引:0,他引:2  
目的 观察乳腺良性疾病不典型增生癌变过程中基底膜的变化。变化 采用SP免疫组化染色法和两种特殊染色方法(Foot及PAS染色法),并利用电镜观察基底膜的变化。结果 Ⅱ级不典型增生的乳腺组织已有基底膜的变化,Ⅲ级不典型增生时基底膜的变化更明显,主要表现为光镜下基底膜明显薄不均,电镜下则可见小的缺失,而乳腺癌组织中基底膜完全缺如。结论 在乳腺上皮细胞癌变过程中基底膜的变化与乳腺上皮细胞的变化密切相关,是乳腺上皮不典型增生癌变过程的一部分。  相似文献   

7.
表皮生长因子(EGF)及其受体(EGFR)在前列腺的正常发育和病理性生长过程中的作用已成为近年来人们关注的焦点之一。本文综述了EGF和EGFR的一般性生物学特性以及在正常前列腺、前列腺增生和前列腺癌中的生物学作用及其与性激素和其他相关生长因子之间的相互关系。  相似文献   

8.
近几十年,在分子肿瘤的研究中发现一些能够促进肿瘤生长、存活的分子,为肿瘤的治疗带来了新的希望.表皮生长因子受体是最早发现的对抑制肿瘤具有重要意义的分子之一,大约50%的三阴性乳腺癌和炎性乳腺癌都过度表达表皮生长因子受体.表皮生长因子受体及其下游通路可以促进上皮问质转化、肿瘤细胞迁移以及肿瘤浸润.此外,由于凋亡信号转导的发生针对表皮生长因子受体治疗可以提高三阴性乳腺癌细胞化疗的敏感性.研究表明,表皮生长因子受体靶向治疗可能对三阴性乳腺癌和炎性乳腺癌的治疗具有重要作用.  相似文献   

9.
目的研究表皮生长因子(EGF)在雌激素受体(ER)阳性及阴性乳腺癌细胞株中对ER表达的影响及其可能的机制。方法以逆转录-聚合酶链反应(RT—PCR)技术分别研究EGF途径以及抑制该途径的信号传导后,对乳腺癌细胞株中ERcxmRNA的影响。结果在ER阳性乳腺癌细胞株中,EGF能显著抑制ERα mRNA的表达(P〈0.05),而通过抑制表皮生长因子受体(EG-FR)、磷脂酰肌醇3激酶(P13K)阻断EGF信号传导可减弱上述抑制作用(P〈0.05);在ER阴性乳腺癌细胞株中,ERα mRNA无显著变化。结论EGF能够明显抑制ER阳性乳腺癌细胞株中ER的表达,这种抑制作用可能通过EGFR、蛋白激酶B(PKB,又称AKt)信号传导途径完成;这种作用在ER阴性乳腺癌细胞株中并不明显。  相似文献   

10.
前列腺增生组织中表皮生长因子受体的免疫组化研究李彦锋,方玉华,李黔生,邓晚洪,江军应用免疫组化方法分析了良性前列腺增生患者(BPH)、青年正常前列腺(YNP)和老年非增生前列腺(ONP)组织中表皮生长因子受体(EGFR)、雄激素受体(AR)、雌激素受...  相似文献   

11.
Both androgen and antiandrogen treatments enhance the proliferation rate of the hormone-dependent prostate cancer cell line LNCaP, expressing a mutated androgen receptor (AR). We studied the modification of the expression of epidermal growth factor (EGF), of its receptor (EGF-R), and of androgen receptor (AR) in the LNCaP cell line, under basal conditions and during androgen (R1881) and antiandrogen hydroxy-flutamide (OH-FLU) treatment. After prolonged R1881 administration, a marked increase of EGF release was observed, completely blocked by the addition of OH-FLU. The Scatchard plot analysis of EGF-R binding revealed two classes of binding sites with high and low affinity. The administration of OH-FLU alone or combined with R1881 did not modify the affinity constants, while the low-affinity component disappeared after androgen administration. Both androgen and antiandrogen administration led to a significant increase of the EGF-R high-affinity component. AR mRNA and protein levels were downregulated by R1881 treatment. Following OH-FLU administration, AR mRNA was slightly downregulated, and there was not a strict parallelism between AR mRNA levels and AR binding capacity. When combined with R1881, OH-FLU partially counteracted the androgen-induced AR downregulation. Our data show that EGF-R binding capacity is the only parameter constantly raised in cell proliferation with respect to quiescent cells, and highlights the nonunivocal action of OH-FLU on androgen-induced effects.  相似文献   

12.
The association between epidermal growth factor receptor (EGFR) expression, clinicopathological variables, silver-stained nuclear organizer region (Ag-NOR) counts, and patient survival was determined in 93 patients with operable breast cancer. The EGFR expression was found to be significantly associated with the presence and number of axillary lymph node metastases (P = 0.0429), but not with age, menopausal status, tumor size, histologic type or grade, or Ag-NOR counts. In a univariate analysis, a significant difference was also observed in the survival of patients stratified by tumor size (P = 0.0091), histologic grade (P = 0.0352), axillarly lymph node metastases (P = 0.0001), and EGFR expression (P = 0.0263). However, a multivariate analysis revealed that axillarly lymph node metastases was the only strong independent predictor ol'survival (P < 0.0001). When axillary lymph node metastases were excluded from the Cox model, the EGFR expression tended to be an independent prognostic factor (P = 0.0558). The results of this study thus indicate that the prognostic value of EGFR expression is limited because the EGFR expression is significantly associated with axillary lymph node metastases.  相似文献   

13.
The expression of human epidermal growth factor (hEGF) was examined immunohistochemically in 86 esophageal cancer lesions, comprising 67 primary tumors and 19 metastatic lymph nodes. In the normal esophagus, the parabasal and intermediate cell layers showed a weak expression of hEGF, however, hEGF-positive tumor cells were detected in 62 (92.5 per cent) of the 67 primary esophageal carcinomas and in 18 (94.7 per cent) of the 19 metastatic lymph nodes. In this study, the immunoreactivity of hEGF was classified into 4 grades according to the number of stained tumor cells. A significant correlation was observed between the histologic type and the grade of hEGF immunoreactivity (Chisquare test, p<0.01). hEGF immunoreactivity in well differentiated squamous cell carcinomas was significantly higher than in other squamous cell carcinomas, although there were no correlations between other pathological findings and hEGF immunoreactivity. Patients with hEGF immunoreactivities of grades II or III had much worse prognoses than those with grades 0 or I (p<0.05). In 22 esophageal carcinomas and 10 normal esophageal mucosae, EGF receptor (EGFR) contents were measured by the competitive binding assay. The average EGFR content (101.3±35.7 fmol/mg protein, mean±SE) of the esophageal carcinomas was significantly higher than that (5.3±1.2) of the normal esophageal mucosae (p<0.05). Moreover, in hEGF negative tumors, EGFR contents were lower than in hEGF positive tumors. These results suggest that hEGF and EGFR show increased production in squamous cell carcinomas and could to be useful prognostic factors in patients with esophageal cancer.  相似文献   

14.
目的:探讨表皮生长因子(EGF)在肥大乳房乳腺组织中的表达及意义。方法:采用免疫组织化学SP法,检测28例肥大乳房和12例正常体积乳房乳腺组织中表皮生长因子(EGF)的表达状况。结果:肥大乳房组28例患者中有19例表皮生长因子(EGF)呈阳性表达(阳性表达率为67.86%),正常体积乳房组12例患者中EGF不表达或呈微弱表达。在本实验中EGF的表达与患者是否有哺乳史及肥大乳房的体积大小没有明显的关系。结论:EGF可能在乳房肥大的发生过程中起着重要作用。  相似文献   

15.
Aim: To investigate mechanisms of tryptase-induced reduction of sperm motility and explore whether epidermal growth factor receptor (EGF-R) and protease activated receptor 2 (PAR-2)- associated pathways are involved. Methods: Fresh semen was collected from healthy donors (n = 15). Semen parameters and quality were assessed in accordance with the World Health Organization (WHO) criteria. Swim-up sperm were fixed and subjected to immunocytochemistry and immunoelectronmicroscopy with specific antibodies directed against PAR-2 and EGF-R. Protein extractions from swim-up spermatozoa were analyzed by Western blotting with antibodies for both receptors. Motility of spermatozoa was evaluated by computer-assisted semen analysis. Results: Immunocytochemistry found PAR-2 and EGF-R in approximately 30% of examined human ejaculated spermatozoa. Both receptors were localized in the plasma membrane. Like tryptase, the PAR-2 synthetic agonist SLIGKV reduced sperm motility, and this effect was inhibited by application of two specific EGF-R pathway blockers (AG1478 and PD168393). Conclusion: The observed reduction of sperm motility by tryptase through the PAR-2 receptor involves EGF-R pathways.  相似文献   

16.
17.
18.
目的探讨人表皮生长因子受体(HER)家族成员[HERl(EGFR)、HER2、HER3和HER4]在胃癌患者中的表达情况及其与预后的关系。方法回顾性分析2006年1月至2006年12月江苏省肿瘤医院胃肿瘤诊疗中心收治的161例胃癌患者的临床资料,应用免疫组织化学方法判断HER家族成员的表达情况,并对其表达与患者预后情况进行分析。结果161例患者中,HERl高表达者74例(46.0%);HER2高表达者17例(10.6%);HER3高表达者90例(55.9%),HER4高表达者110例(68.3%)。单因素分析显示:HER2高表达与肿瘤Lauren分型有关(P〈0.05);HER3高表达与肿瘤浸润深度、淋巴结转移、肿瘤分期和神经脉管侵犯及预后有关(P〈O.05);HER4高表达与肿瘤浸润深度和远处转移及肿瘤分期有关(P〈O.05)。HER2-HER3协同高表达与患者预后有关(P=0.023)。多因素分析显示:肿瘤分期和HER3高表达是影响胃癌预后的因素(P〈0.05)。结论HER3有可能成为评价胃癌预后的独立因素。  相似文献   

19.
目的 探讨肝细胞生长因子受体(Met)及表皮生长因子受体(EGFR)在胰腺癌临床病理和生存预后中的意义.方法 回顾性分析1995至2005年间收治的70例胰腺癌患者的临床病理数据及随访资料,以免疫组织化学染色法(EnVision法)检测Met和EGFR在胰腺癌病理石蜡组织中的表达水平,分析其与临床病理指标的关系,并探讨两种受体表达水平之间的相关性;对总生存时间进行Kaplan-Meier生存分析及相关风险因素的Cox回归检验.结果 Met和EGFR与胰腺癌TNM临床分期、肿瘤大小、血管侵犯相关(P<0.05).Met和EGFR的表达水平呈正相关(rp=0.658,P<0.05),两者的表达水平与患者生存时间相关(P<0.05).Met为影响预后的独立危险因素.结论 Met和EGFR与胰腺癌的生物学行为及临床预后相关;两种受体存在相关性.胰腺癌的靶向治疗策略应兼顾Met及EGFR.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号